Almac Group Reports Record £1.027 Billion Revenue for FY2024

• Almac Group reported a record revenue of £1.027 billion for the financial year ending 30 September 2024, a 7% increase year-on-year.

• Pre-tax profits rose by 27% to £119 million, and global employee numbers grew by 3%, reaching over 7,700.

Almac Group, the global contract pharmaceutical development and manufacturing organisation (CDMO), has announced record-breaking financial results for its fiscal year ending 30 September 2024. The company posted £1.027 billion in revenue, a 7% increase from the previous year, alongside a 27% rise in pre-tax profits to £119 million.

These results form part of the fourth year of Almac’s £400 million-plus global capital investment programme, launched in 2021. Projects under this programme include a Centre of Excellence for diagnostic development, a 100,000 sq ft pharmaceutical manufacturing facility, and expanded cryogenic and ultra-low temperature services in North Carolina and Singapore. A major expansion also continues in clinical production and distribution at Souderton, Pennsylvania.

Headquartered in Northern Ireland, Almac now employs more than 7,700 people worldwide. During the financial year, the group contributed to the development of hundreds of drug programmes across more than 20 therapeutic areas, including oncology, cardiology, immunology, gene therapy, and neurology.

“All our profits are reinvested into the business, enabling us to innovate and expand to meet the growing needs of our global clients,” said Alan Armstrong, Chairman and CEO of Almac Group.